TABLE 3.
Geometric mean titers and geometric mean concentrations of antibodies against vaccine antigens 1 month after vaccination
| Parametera | Value (95% CI) for the groupb vaccinated with: |
||
|---|---|---|---|
| MenACWY-CRM + Tdap (n = 356) | MenACWY-CRM + saline placebo (n = 357) | Tdap + saline placebo (n = 352) | |
| Geometric mean titers | |||
| MenA | 34 (23-50) | 50 (34-74) | NAc |
| MenC | 89 (58-136) | 92 (60-140) | NA |
| MenW-135 | 73 (54-98) | 77 (57-103) | NA |
| MenY | 73 (54-98) | 70 (52-94) | NA |
| Geometric mean concns | |||
| Anti-diphtheria (IU/ml) | 8 (6-10) | NA | 3 (2-4) |
| Anti-tetanus (IU/ml) | 12 (10-14) | NA | 15 (13-18) |
| Anti-PT (EU/ml) | 62 (52-74) | NA | 79 (66-93) |
| Anti-FHA (EU/ml) | 186 (165-209) | NA | 219 (194-246) |
| Anti-PRN (EU/ml) | 157 (131-189) | NA | 254 (211-304) |
a
GMTs and GMCs were rounded down when the first decimal was ≤0.5 and were rounded up when the first decimal was >0.5. GMTs are all SBA inverse titers. PT, pertussis toxoid; FHA, filamentous hemagglutinin; PRN, pertactin.
b
MenACWY-CRM, quadrivalent meningococcal conjugate vaccine; Tdap, combined tetanus, reduced diphtheria, and acellular pertussis vaccine.
c
NA, not applicable.